By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    benefits of using protein powder to build muscles
    Protein Powder for Muscle Mass: Everything You Need to Know
    December 12, 2021
    changes brought on by blockchain in healthcare
    Technology In The Healthcare Industry
    March 28, 2022
    What Does Core Body Temperature Say About Health?
    August 17, 2022
    Latest News
    Health Benefits of Taking a Vacation to Reduce Your Stress
    September 27, 2023
    First Aid Training Enhancing Workplace Health and Safety
    September 25, 2023
    Beyond the Clinic: Medical Surveys Are a Roadmap to Passive Income for Doctors
    September 23, 2023
    5 Self-Care Habits to Help You Live an A+ Life
    September 21, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    A Short Guide To Medical Waste Management For Every Facility
    August 12, 2020
    More on the Longevity Project
    August 26, 2017
    Ultraprocessed Foods Lead to Chronic Illnesses
    April 18, 2011
    Latest News
    Job Seekers with Disabilities Should at Health Insurance Benefits
    September 12, 2023
    Reasons That Drug Prices Are Rising to Unsustainable Levels
    September 12, 2023
    How Revenue Lifecycle Management Helps Healthcare Providers to Optimize Business Operations
    September 6, 2023
    The Hidden Benefits of Practice Exams for Medical Professionals
    September 6, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: ImmunoGenetix Discovers a Safer Approach To HIV Treatment
Share
Sign In
Notification Show More
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > ImmunoGenetix Discovers a Safer Approach To HIV Treatment
Medical Innovations

ImmunoGenetix Discovers a Safer Approach To HIV Treatment

HerinaAyot
Last updated: 2011/09/19 at 6:15 PM
HerinaAyot
Share
14 Min Read
SHARE

James Laufenberg, CEO of ImmunoGenetix was interviewed by OneMedRadio where he discussed a therapeutic DNA based composition to treat HIV, GenePro. “The idea with GenePro is that what we want to do is synthetically mimic a virus so that there’s an effective stimulation of the immune system,” Jim says. Considering this safer approach to HIV treatment, the company has a promising future. See audio and transcribed interview below.

 

James Laufenberg, CEO of ImmunoGenetix was interviewed by OneMedRadio where he discussed a therapeutic DNA based composition to treat HIV, GenePro. “The idea with GenePro is that what we want to do is synthetically mimic a virus so that there’s an effective stimulation of the immune system,” Jim says. Considering this safer approach to HIV treatment, the company has a promising future. See audio and transcribed interview below.

 

More Read

AI helps healthcare providers with record keeping through the use of medical code extraction

Medical Code Extraction Using Artificial Intelligence

Maximizing Outcomes Through Effective Patient Engagement Strategies
Why Is Testing for HIV At Home Convenient For You?
Materials and Techniques for Taking Dental Impressions
How Technology Tools Can Benefit Physicians and Patients

Brett Johnson: Good day, this is Brett Johnson with OneMed Radio in New York City. Today, we are with Jim Laufenberg, who is the chief executive officer of ImmunoGenetix, a Lenexa, Kansas based firm that’s developed vaccine treatments for HIV called GenePro. Jim, thanks for joining us today.

Jim Laufenberg:          Well, thank you, Brett, for having me.

BJ: So can you tell us a little bit about GenePro and where you are in its development?

JL: Yes. GenePro is a therapeutic DNA based composition that we have taken out of the University of Kansas by an inventor that was recruited there from Johns Hopkins, Dr. Opendra Narayan. He’s a well published and received over $20 million in NIH funding towards this composition. We have published in the non-human primate and we’ve had our meeting, initial pre-I&D meeting with the Food and Drug Administration and we’re engaging in that process.

So we’re rather teed up on a number of exciting things to move forward now to open up our I&D. What we need to complete now are two I&D enabling studies and we’re using a delivery device called the TriGrid electroporation delivery. So we’re partnering with Ichor Medical Systems in San Diego and most of the developers in DNA vaccines are looking at electroporation to enhance uptake of this molecule.

BJ: Uh-hum.

JL: We anticipate, you know, doing our obviously safety, toxicology, and some immunogenicity data going forward and if everything goes according to plan, we’ll open our I&D next year to initiate a phase I2a clinical trial.

BJ:       Sure.

JL: And I’m sure it’d be positive. Yup.

BJ: So what does GenePro do and what problem does it solve?

JL: Well, currently, HIV is being treated by anti-retroviral therapy known as drug cocktails. So there are about a dozen drugs that clinicians use and they manipulate these drugs and use three or four at any given time in their HIV-positive patients. Unfortunately, these drugs are starting to show resistance that are being developed and one out of four patients will develop drug resistance to one of those drugs and also some very untoward side effects such as increased fat and sugar in the blood stream. So, you know, while they have been somewhat of godsend in treating HIV from developing into AIDS over the past decade, there is an unmet need to have new approaches.

DNA vaccines and GenePro have the promise of reconstituting the immune system so that our natural immune defenses can find this virus, attack it, and bring it down. We could talk a little bit about some very recent findings around what are called elite controllers if you’d like to get into that, Brett.

BJ: Sure. If you can give us sort of a layman’s description of how this stuff works, that’d be fine.

JL: So, what happens is that there is a white blood cell that will attack viruses as they enter our body and in HIV, we don’t do a very good job of detecting that virus. But there’s a small population in society that can normally suppress this virus and they’re called elite controllers or long-term non-progressors. Well these elite controllers, about 3% of the population generate this very specific white blood cell called the CD8 memory cell specific to HIV and they can actually control this virus without having drugs on board, and that recently was found and published in reputable journal.

We have published data both in the mouse model as well as the macaque Rhesus model showing that we generate this specific type of white blood cell, the CD8 memory cell. So that GenePro can actually find the virus, take it down to undetectable levels, and then allow these memory cells to lie low in case that virus reappears. That’s very exciting. There was a lot of language going on right now saying that this s a functional cure in the industry and the area of HIV and AIDS is focused on these functional cures such as potentially what GenePro has.

BJ: Sounds very exciting. So where did the technology come from and can you tell us a bit about the background on the science?

JL: Well, yes. The technology came from the University Kansas Viral Pathogenesis Lab. Its director was Dr. Opendra Narayan. He is now deceased. He was affectionately known as Bill and Bill was widely published in over 150 peer-reviewed journal articles and again substantial funding from the NIH through a series of R01 grants. This vaccine essentially has been passaged through various animal models rendering it relatively safe.

The idea with GenePro is that what we want to do is synthetically mimic a virus so that it’s very important so that there’s an effective stimulation of the immune system, a natural stimulation of the immune system. So therefore, it’s a rather aggressive composition with seven genes representing this virus and a series of genes that are deleted or left off so that GenePro does not cause safety issues such as integration into the body itself.

BJ: I see. So in terms of getting this into the market now, where are you at in the development of this product?

JL: We’re completing what we hope is the remaining I&D enabling studies in rat and rabbit and hopefully opening an I&D about this time next year to enter into a phase I2a clinical trial in 30 to 40 HIV-positive patients. We’d like to hold that trial close by at the University of Kansas if possible so that we can recruit locally, but also receive some economic development grants and also support with the National Institutes of Health. Therefore, we would obtain both safety data in man and efficacy data somewhere in the timeframe of the end of 2013 if everything goes according to plan.

What we hope to do during that process is to attract enough attention from the industry to provide partnership capabilities to move forward after that point.

BJ: Terrific. Can you talk about from a corporate side in terms of investment that has gone into the company and who’s invested and how much you’re looking to raise in the future?

JL: Right. So, Brett, we have a very clean cap table consisting of accredited angel investors and that’s all in common stock, voting stock and that’s about half of our cap table. The other half of our cap table is economic development convertible notes. And we have a small preferred series A stock that actually can be bought out. So again, that’s a relatively clean cap table with a pre-money valuation of $8 million based upon fully diluted share at a dollar a share.

BJ: And you’re looking to raise how much?

JL: Yeah. Well, currently, we’re concluding a $1 million round. In addition to that, we have a matching about a half million dollars that was announced from the Kansas Bioscience Authority and that’s a non-dilutive grant for this developmental activity and these are pre-I&D activities right now.

And in the State of Kansas we can use transferrable Kansas angel tax credits for high net worth individuals who invest between $50,000 to $100,000, they actually get a 50% tax credit. For those high net worth individuals that are out of the state of Kansas, there’s actually a market for those tax credits. So it’s really a great way to influence development of unique technology in the state of Kansas and that’s why we’re in Kansas.

Then when we go out to San Francisco in January, we will be launching a $5 million round in order to anticipate our phase I2a clinical trial.

BJ: Perfect. Can you tell us a little bit about your background and the other members of the management team?

JL: Right. So we have a small board of directors, there are five of us and I’m sure of that. My background is a business background. I have an MBA. I have 25 years at Marion Laboratories and its iterations now, so Sanofi-Aventis. The other members of our board are all industry-specific individual, deep experience. We have an entrepreneur out in San Francisco Dr. Bill Garner who has Harvard training. He’s launched a number of companies and he provides really good scientific advice as well. The other members of our board have finance, legal, and foundation and human resource. The most important thing I can say about our board is that we’re all on the same page. We understand our exit points and our mission to have a return for our investors with an appropriate exit.

BJ:    Terrific. Can you talk a little bit about sort of the scope for this opportunity and what the possibilities can be for GenePro?

JL: Right. Brett, the promise of GenePro technology and DNA vaccines generally is that they can change the way these diseases are treated in a safer approach. Specific to GenePro, we would anticipate a clinician being able to put their patients on GenePro, deliver it on a quarterly basis in the clinic much like oncology drugs are delivered. And then as the patients are monitored with the viral load and a different type of white blood cell, CD4, measured, they could provide drug holidays for their patients on these toxic drug cocktails.

As clinicians gain experience with GenePro, they could delay the onset usage of the drug cocktails as well and I think clinicians would really welcome that type of flexibility. Of course what that also could do, by allowing a reduction in current standard of care drug therapy, you could more than likely reduce the overall cost of healthcare.

BJ: Well certainly that would be something welcomed in this day and age. That is Jim Laufenberg who is the CEO of ImmunoGenetix, a Lenexa, Kansas private firm that has developed GenePro, an interesting treatment for HIV. Thanks for joining us today, Jim.

JL: Thank you, Brett. Have a great day.

 

TAGGED: AIDS, GenePro, HIV, ImmunoGenetix

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
HerinaAyot September 19, 2011
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Taking 23 Drugs From 4 Different Doctors – Lousy But Expensive Care
Next Article The Genomic Revolution–Sequencing and Treating Disease (Video)

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

Andropause hormonal decline
The Benefits of TRT for Andropause and Hormonal Decline
Wellness September 28, 2023
Cancer Prevention
The Importance of Lipoma Examination in Cancer Prevention
Cancer September 28, 2023
dental implant
Cost Analysis of Dental Implants in Australia
Dental health September 28, 2023
View,Of,Niagara,Falls,In,Autumn
Health Benefits of Taking a Vacation to Reduce Your Stress
Health September 27, 2023

You Might also Like

medical interpreters
Medical Innovations

The Vital Role of Medical Interpreting Services In Healthcare

April 21, 2023
virtual reality in optometry
Technology

Virtual Reality Visual Field Test Device in Healthcare

March 22, 2023
benefits of EHR systems in healthcare
Technology

Using EHR systems in healthcare for Cost-Effective Services

February 9, 2023
healthcare seo tips
Medical Innovations

Healthcare SEO Tips to Grow Your Medical Practice

February 8, 2023
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?